Steffan Daniel Bos-Haugen has held a position as a researcher at the Cancer Registry of Norway since 2023. He works with research related to the Janus Serum Bank, with primary focus on the use of -omics methods to find risk factors and early markers for cancer, markers for treatment repsonse and course of disease. Bos-Haugen holds a Master's degree in Biopharmacy from the University of Leiden in the Netherlands from 2004. He obtained a doctorate from the University of Leiden, the Netherlands in 2010 by successfully defending his thesis focusing on osteoarthritis and inflammation.
Steffan performs research activities related to the Janus Serum Bank, with a primary focus on the use of -omics methods to find risk factors and early markers for cancer, markers for treatment repsons and course of disease.
Steffan holds a Master's degree in Biopharmacy from the University of Leiden, The Netherlands (2004). At the same university, Steffen has completed a PhD project focusing on arthritis and inflammation (2010).
From 2010 to 2012, Steffan worked as a postdoctoral fellow at the Leiden-based consortium 'Netherlands Consortium for Healthy Ageing' – NCHA. In this position, he has researched how people have different ageing and how the musculoskeletal system is affected by ageing.
Between 2012 and 2021, Steffan has worked as a researcher and senior researcher at the University of Oslo and Oslo University Hospital in the research group for multiple sclerosis (MS). In this position he has contributed to and led studies where -omics in MS was central.
From 2021 to 2023, Steffan has worked at the Department of Medical Genetics at the University of Oslo where the focus has shifted to cancer research, with the main focus on how germline genetic variation contributes to the risk of developing cancer.
From 2023, Steffan holds a position as a researcher at the Cancer Registry
